Skip to content

TYBR Health

Surgical gel that limits scarring after tendon repair

Raised to date

$14.4M

of $30M offered across 1 Form D filing

Still open
$15.6M
Investors
12
Last filed
Jul 22, 2026

About

TYBR Health is a Houston, Texas medical device company founded in 2020 that develops biomaterials to protect healing tissue after surgery. Its lead product, the B3 GEL System, is a flowable extracellular-matrix hydrogel applied at the end of tendon and ligament repair procedures to keep healing tissue from tethering to surrounding structures. The company is a Y Combinator Winter 2022 company and has been backed by MedTech Innovator, the National Institutes of Health, Creative Destruction Lab and JLABS. It has enrolled its first patients in a clinical trial of the B3 GEL System in tendon surgery.

A naturally derived, brilliant-blue-tinted flowable ECM hydrogel that maintains biomechanical separation during the critical healing window, rather than a physical membrane or barrier film that carries mechanical impingement risk.

Funding

  • EquityFiled Jul 22, 2026Form D
    $14.4M/ $30M

Product

B3 GEL System

Surgical biomaterial / medical device

A flowable, extracellular-matrix-based protective gel delivered during surgery that coats repaired tendons and adjacent tissue to limit restrictive scar formation and preserve gliding motion during healing.

  • Flowable ECM-based gel that conforms to irregular tissue surfaces
  • Brilliant blue tint for precise visualization during surgical application
  • Maintains biomechanical separation through the critical healing phase

Built for

Orthopedic and hand surgeons and the hospitals and surgical practices performing tendon and ligament repair, primarily hand and wrist procedures

People on file